Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.
Jose Maria Jimenez Alvir, DrPH
Advertisement
Articles by Jose Maria Jimenez Alvir, DrPH
Advertisement
Latest Updated Articles
- Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice
Published: February 9th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
3
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
4
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
5